James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the antibody subtypes associated with this rare neuromuscular disease.
Myasthenia gravis treatment needs to be customized to the needs of individual patients, according to James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, former chief of the Neuromuscular Disorders Division, and former James F. Howard Distinguished Professor of Neuromuscular Disease. In this interview, he explained the antibody subtypes associated with this rare neuromuscular disease.
Transcript
What are some of the key differences in myasthenia gravis, depending on the antibody subtype?
So, acetylcholine receptor antibody–positive is the largest group we see, representing somewhere around 85%. And the numbers change as our technology improves and we can identify newer antibodies. MuSK [muscle specific kinase] myasthenia represents 8% to 9%. LRP4 [lipoprotein-related protein 4] is down around 1% or less. Then there's a group of patients for which we have not identified an antibody as yet. There is some circulating factor, I believe, as they respond to things like plasma exchange or antibody clearance drugs, etc. It’s important to recognize which antibody one has, because our therapeutic options change. For instance, MuSK myasthenia does not respond to surgical thymectomy. [These patients are] very often, in more than 70%, hypersensitive or allergic or intolerant of a class of drugs called cholinesterase inhibitors, most commonly pyridostigmine, or Mestinon.
And so it's important that these antibody subtypes be identified in order that we can plan the appropriate therapeutic intervention. The treatment of myasthenia is not a cookbook. It has to be tailored to the specific individual in the US based on a whole host of factors, not the least of which is the financial resources that they have.
But their comorbidities, the pattern of muscle weakness, the rapidity with which that weakness came on—so if someone has smoldering weakness in arms and legs, it will be treated totally different than if one comes in saying I can't chew, swallow, or I'm having respiratory difficulties—and knowing which antibody subtype often helps in determining what will be our overall game plan.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More